Livestream: The Force Awakens—Unlocking the Potential of IL-23–targeted Therapies in the Treatment of IBD

The therapeutic armamentarium for inflammatory bowel disease (IBD) is expanding with the advent of anti–IL-23 therapies. The unique clinical profiles of new and emerging agents make it necessary that treatment decisions are guided by evolving knowledge of the science surrounding cytokine-targeting therapies. With an established efficacy in treating both bio-naïve and bio-experienced patients, and the increased flexibility in administration routes (intravenous vs subcutaneous), the growing class of distinctive IL-23–targeting agents amplifies the importance of clinicians utilizing the most current research and guidelines when determining with patients where to best position IL-23 agents in the treatment of their IBD.

In this CME Outfitters livestream symposium, faculty will examine how pro-inflammatory cytokines drive inflammation in the pathogenesis of IBD, explore the role of the IL-23/Th17 inflammatory axis in IBD pathogenesis, and discuss the clinical implications of Anti–IL-23 agents used in the treatment of IBD to bind to CD64 receptors on IL-23–producing cells.

Learning Objectives

At the conclusion of this activity, learners will be able to better:

Assess the role of pro-inflammatory cytokines such as IL-23 in the pathogenesis of IBD
Differentiate IL-23 binding among the IL-23p19–targeted therapies
Evaluate the safety and efficacy of IL-23p19–targeted therapies available for the treatment of IBD
Incorporate IL-23p19–targeted therapies into the multidisciplinary management of appropriate patients with IBD

Financial Support

Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, both are Johnson and Johnson companies.

Target Audience

Gastroenterologists, gastroenterology fellows/trainees, physician associates (PAs), nurse practitioners (NPs), and nurses

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physicians (ACCME) 1.5

CME Outfitters, LLC, designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) 1.5

This activity is designated for 1.50 contact hours.

California Residents: This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC’s provider number is CEP15510.

Physician Assistants (AAPA): 1.5

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.50 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

ABIM MOC 1.5

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. Relevant financial relationships exist between the following individuals and commercial interests:

Dr. Regueiro reports the following financial relationships:

Consultant: AbbVie Inc; Amgen Inc.; Boehringer Ingelheim; Bristol Myers Squibb Company; Celgene Corporation; Genentech, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Pfizer Inc.; Prometheus Biosciences, Inc.; Salix Pharmaceuticals; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc.

Ms. Kametas reports the following financial relationships:

Advisory Board: Lilly and Pfizer Inc.

Consultant: TKG Therapeutics, Inc.

Grants: GI Research Foundation

Speakers Bureau: AbbVie Inc.; Janssen Pharmaceuticals, Inc.; and Pfizer Inc.

Dr. Loftus reports the following financial relationships:

Advisory Board: Lilly and Morphic Therapeutic, Inc.

Consultant: AbbVie Inc.; Alvotech; Amgen Inc.; Arena Pharmaceuticals, Inc.; Astellas Pharma Inc.; Avalo Therapeutics, Inc.; Boehringer Ingelheim; Bristol Myers Squibb Company; Celltrion, Inc.; Fresenius Kabi; Genentech, Inc.; Gilead Sciences, Inc.; GlaxoSmithKline; Gossamer Bio; Iterative Health; Janssen Pharmaceuticals, Inc.; Ono Pharma USA, Inc.; Protagonist Therapeutics Inc.; Sun. Pharma; Surrozen; Takeda Pharmaceuticals U.S.A.; TR1X Bio; and UCB, Inc.

Grants: AbbVie Inc.; AstraZeneca; Bristol Myers Squibb Company; Celgene Corporation/Receptos, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Takeda Pharmaceuticals U.S.A.; Theravance Biopharma; and UCB, Inc.

Stock Shareholder (directly purchased): Exact Sciences Corporation

Dr. Long reports the following financial relationships:

Consultant: AbbVie Inc.; Bristol Myers Squibb Company; Intercept Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Pfizer Inc.; Prometheus Biosciences, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and Target RWE

Research Support: Lilly; Pfizer Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

The following individuals have no financial relationships to disclose:

Rebecca Vargas-Jackson, MD (Peer Reviewer)
Albert Eubanks, Jr., RN (Peer Reviewer)
Chelsey Goins, PhD (Planning Committee)
Nichole Lainhart (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

*All identified conflicts of interest have been mitigated.

Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CME Outfitters, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (0% pass rate required). This website supports all browsers except Internet Explorer for Mac.